cellpenetr
peptid
cpp
short
cation
peptid
extens
studi
drug
deliveri
vehicl
protein
nucleic
acid
nanoparticl
howev
formul
cppbase
therapeut
differ
pharmaceut
formul
stabil
relev
biolog
environ
given
attent
show
newli
develop
cpp
pepfect
form
noncoval
nanocomplex
short
interf
rna
sirna
abl
elicit
effici
rnainterfer
rnai
respons
differ
celllin
rnai
effect
obtain
low
sirna
dose
uniqu
kinet
profil
furthermor
solid
dispers
techniqu
util
formul
nanocomplex
solid
formul
activ
freshli
prepar
nanocomplex
solut
importantli
nanocomplex
stabl
activ
mediat
rnai
respons
incub
simul
gastric
fluid
sgf
highli
acid
result
demonstr
activ
deliv
protect
sirna
differ
pharmaceut
form
biolog
environ
oligonucleotid
base
therapeut
recent
gain
much
interest
promis
drug
candid
abil
easili
design
on
specif
repair
patholog
genet
defect
either
dna
rna
level
remark
advantag
compar
expens
timeconsum
screen
requir
small
molecul
drug
addit
specif
target
particular
gene
lead
fewer
side
effect
among
therapeut
modal
includ
antisens
antigen
spliceswitch
on
sirna
gain
special
interest
make
sirna
appeal
approach
cleav
target
mrna
catalyt
manner
help
risc
complex
thu
lower
dose
requir
achiev
gene
knockdown
compar
convent
antisens
approach
howev
therapeut
sirna
larg
hydrophil
molecul
bypass
hydrophob
plasma
membran
barrier
reach
target
mrna
cytoplasm
tremend
research
effort
put
develop
deliveri
system
sirna
one
class
vector
could
promis
deliv
sirna
therapeut
cellpenetr
peptid
cpp
cpp
polybas
andor
amphipath
peptid
usual
less
amino
acid
length
abl
travers
plasma
membran
even
coupl
larg
molecul
nanoparticl
cargo
either
coval
link
noncoval
complex
cpp
noncoval
complex
strategi
advantag
simpl
versatil
thu
sever
cpp
util
deliv
protein
peptid
plasmid
on
via
noncoval
complex
group
gill
divita
first
show
cpp
use
deliv
on
noncoval
complex
use
mpg
peptid
net
posit
charg
mpg
shown
form
nanocomplex
neg
charg
singleand
doublestrand
on
effici
intern
cell
sinc
initi
public
sever
cpp
develop
form
nanocomplex
variou
nucleic
acid
effici
mediat
deliveri
sever
invitro
invivo
set
howev
certain
chemic
modif
cpp
need
improv
nanoparticl
format
capabl
enhanc
membran
interact
upon
noncoval
complex
ctermin
cysteamid
modif
shown
crucial
cppmediat
sirna
deliveri
use
mpg
pep
cadi
peptid
famili
increas
membran
associ
stabil
particl
format
format
peptid
dimer
acetyl
peptid
also
requir
enhanc
stabil
addit
hydrophob
moieti
cpp
shown
effici
mean
increas
effici
nanocomplex
cholesteryl
modif
polyarginin
demonstr
enhanc
activ
deliveri
sirna
invivo
group
shiroh
futaki
kyoto
univers
first
demonstr
stearyl
polyarginin
could
enhanc
transfect
effici
recent
year
group
appli
stearyl
chemic
modif
backbon
lead
develop
pepfect
famili
peptid
pf
stearyl
enabl
peptid
form
stabl
nanocomplex
nucleic
acid
drastic
enhanc
transfect
effici
compar
nonstearyl
counterpart
among
pepfect
famili
shown
mediat
effici
splice
correct
activ
variou
cell
line
complex
spliceswitch
on
furthermor
found
nanocomplex
dri
stabl
solid
formul
via
soliddispers
techniqu
util
convent
pharmaceut
excipi
show
also
capabl
effici
deliv
sirna
variou
cell
line
liquid
solid
form
importantli
show
solid
formul
stabl
acid
simul
gastric
condit
synthes
purifi
describ
earlier
two
sirna
target
firefli
luciferas
hypoxanthin
phosphoribosyl
transferas
synthes
purifi
ge
healthcar
uppsala
sweden
sequenc
sirna
luciferas
sens
antisens
sens
antisens
unrel
sirna
synthes
sigma
sweden
sequenc
sens
antisens
sirna
store
aliquot
luciferas
stabl
cell
line
babi
hamster
kidney
cell
human
hepatocellular
carcinoma
human
embryon
kidney
hek
cell
use
test
effici
formul
sirna
downregul
luciferas
express
luciferasest
cell
gener
lipofect
luciferas
plasmid
clontech
select
hygromycin
sigma
luciferasest
hek
cell
kindli
provid
professor
paavo
honkakoski
univers
kuopio
describ
previous
luciferasest
cell
gener
lentivir
transduct
control
cmv
promot
human
hepatocellular
carcinoma
cell
line
huh
bought
atcc
access
number
use
test
knock
endogen
gene
cell
line
grown
dmem
medium
glutamax
invitrogen
sweden
supplement
fetal
bovin
serum
fb
invitrogen
jurkat
cell
atcc
grown
media
supplement
mm
nonessenti
amino
acid
mm
sodium
pyruv
antibiot
uml
penicillin
mgml
streptomycin
cell
maintain
co
humidifi
incub
one
day
prior
transfect
cell
seed
cell
per
well
jurkat
cell
seed
per
well
plate
aqueou
solut
ad
cell
give
final
concentr
sirna
rang
nm
transfect
perform
serum
serumfre
condit
serum
ad
cell
final
concentr
h
transfect
known
transfect
reagent
lipofectamin
lf
lipofectamin
lf
rnaimax
invitogen
use
control
end
experi
cell
either
lyse
use
lysi
buffer
triton
pb
subsequ
luciferas
total
protein
measur
trypsin
save
pellet
isol
rna
lyse
cell
luciferas
activ
assess
use
correspond
substrat
promega
sweden
monitor
micropl
luminomet
promega
total
protein
measur
use
lowri
method
biorad
usa
micro
protein
assay
kit
thermo
scientificpierc
protein
research
product
accord
manufactur
protocol
nanocomplex
form
mix
sirna
min
room
temperatur
meanwhil
cell
medium
replac
well
fresh
serumfre
serumcontain
medium
ml
thereaft
complex
ad
well
use
lf
rnaimax
invitrogen
sweden
complex
prepar
accord
manufactur
protocol
prepar
solid
formul
use
mannitol
duchefa
biochemi
holland
solid
dispers
matrix
mannitol
solut
prepar
concentr
mgml
mq
water
ad
aqueou
solut
nanocomplex
give
final
concentr
mixtur
thereaft
dri
savant
dna
speedvac
model
dna
h
temperatur
rang
dri
powder
reconstitut
water
simul
gastric
fluid
sgf
ad
cell
medium
without
serum
cell
experi
physic
character
total
rna
isol
cell
pellet
use
rneasi
plu
kit
qiagen
sweden
rna
analyz
use
multiplex
q
rtpcr
amplifi
gapdh
endogen
control
assay
perform
use
multiplex
rtpcr
kit
qiagen
sequenc
primer
probe
gapdh
sigma
follow
gapdhfwd
gapdhrev
taqman
probe
joe
tgactccgaccttcaccttcc
gapdh
taqman
probe
tgccagtgtcaattatatcttccacaa
joe
two
fluorophor
differ
emiss
spectra
black
hole
quencher
use
quencher
multiplex
q
rtpcr
reaction
setup
done
accord
kit
protocol
ng
rna
use
reaction
final
volum
reaction
standard
curv
made
run
use
known
amount
rna
serial
dilut
order
confirm
effici
pcr
cycl
condit
pcr
min
revers
transcript
min
pcr
initi
activ
step
cycl
step
denatur
annealingextens
quantit
pcr
perform
use
real
time
pcr
system
appli
biosystem
sweden
data
analyz
method
use
softwar
version
size
nanocomplex
either
freshli
prepar
solid
formul
measur
use
newli
develop
method
known
nanoparticl
track
analysi
nta
fresh
nanocomplex
measur
water
invitrogen
fb
solid
formul
measur
dissolv
water
simul
gastric
fluid
sgf
without
pepsin
fb
nta
measur
perform
nanosight
nanosight
amesburi
uk
equip
sampl
chamber
nm
laser
ml
sampl
inject
sampl
chamber
steril
dispos
syring
measur
perform
room
temperatur
nanosight
softwar
use
captur
analyz
data
sampl
measur
manual
shutter
gain
adjust
mean
size
mode
standard
deviat
sd
calcul
togeth
cumul
size
valu
sampl
concentr
nanocomplex
sampl
measur
machin
sec
video
clip
file
show
particl
move
brownian
motion
taken
sampl
zeta
potenti
measur
carri
use
delsananoc
beckman
coulter
accord
manufactur
protocol
acid
stabil
assess
sgf
prepar
accord
us
pharmacopeia
briefli
sgf
solut
wv
nacl
wv
purifi
pepsin
sigma
vv
conc
hcl
ph
nanocomplex
solid
formul
resuspend
incub
sgf
nanocomplex
solut
mix
incub
doublestrength
sgf
nacl
pepsin
hcl
retain
equival
sgf
condit
without
dilut
incub
mixtur
ad
cell
serum
free
condit
h
follow
addit
serum
final
concentr
control
well
sgf
ad
h
cell
lyse
luciferas
assay
togeth
total
protein
measur
perform
state
earlier
downregul
luciferas
activ
normal
express
level
control
well
treat
sgf
test
abil
nanocomplex
downregul
luciferas
express
celllin
stabli
express
luciferas
serum
serumfre
condit
screen
sever
peptidesirna
molar
ratio
mr
differ
dose
titrat
transfect
util
serumfre
medium
result
knockdown
dose
nm
sirna
mr
less
effici
fig
serumcontain
medium
nanocomplex
mediat
knockdown
util
nm
sirna
fig
serumfre
serum
contain
media
nanocomplex
surpass
activ
furthermor
perform
dose
titrat
use
celllin
stabli
express
luciferas
comparison
lf
rnaimax
optim
sirna
deliveri
nanocomplex
display
superior
activ
doserespons
manner
use
dose
fig
result
demonstr
effici
deliv
sirna
cell
mediat
profound
rnai
effect
gene
knockdown
rel
low
dose
dosedepend
manner
order
learn
effici
kinet
gene
downregul
nanocomplex
assess
silenc
endogen
gene
cell
doserespons
experi
found
concentr
mrna
deplet
ec
nm
nm
serumcontain
serumfre
condit
respect
fig
addit
ran
kinet
experi
use
dose
nm
downregul
upon
transfect
record
h
follow
day
nanocomplex
mediat
extrem
fast
effect
sinc
deplet
mrna
reach
h
effect
significantli
higher
effect
mediat
wellknown
transfect
reagent
lf
moreov
nanocomplex
effici
maintain
silenc
mrna
day
last
time
point
test
line
nanocomplex
also
mediat
effici
knockdown
mrna
jurkat
cell
regard
hardtotransfect
celllin
supplementari
fig
similar
procedur
use
formul
nanocomplex
spliceswitch
on
formul
solid
formul
via
solid
dispers
techniqu
upon
screen
sever
excipi
differ
concentr
mannitol
final
concentr
optim
data
shown
method
preform
nanocomplex
mix
certain
volum
mannitol
solut
subsequ
mixtur
dri
use
speedvac
interestingli
resuspens
addit
cell
mannitolbas
solid
formul
demonstr
rnai
activ
similar
freshli
prepar
nanocomplex
fig
ensur
presenc
nanocomplex
stabil
rel
harsh
solid
dispers
procedur
perform
detail
particl
size
analysi
use
nta
techniqu
nta
new
system
size
particl
first
commerci
techniqu
combin
laser
light
scatter
microscopi
ccd
camera
enabl
visual
record
nanoparticl
solut
nta
softwar
abl
identifi
track
individu
nanoparticl
move
brownian
motion
relat
movement
particl
size
accord
formula
deriv
stokeseinstein
equat
particlebyparticl
methodolog
provid
highresolut
particl
size
distribut
compar
tradit
light
scatter
ensembl
techniqu
addit
measur
concentr
valid
data
video
file
particl
move
brownian
motion
freshli
prepar
formul
show
particl
size
mean
nm
measur
water
insignificantli
differ
measur
serumcontain
medium
demonstr
toler
particl
serum
solid
formul
measur
show
mean
particl
size
nm
insignificantli
differ
formul
measur
serumcontain
medium
similar
demonstr
stabil
particl
solid
dispers
procedur
fig
addit
measur
zeta
potenti
nanocomplex
solid
formul
determin
surfac
properti
crucial
activ
found
resuspend
water
nanocomplex
possess
posit
zeta
potenti
mv
howev
resuspend
biorelev
medium
zeta
potenti
revers
neg
valu
mv
mv
absenc
presenc
serum
respect
trend
follow
pattern
demonstr
nanocomplex
spliceswitch
on
highlight
effect
medium
physic
properti
henc
uptak
mechan
nanocomplex
wide
use
applic
solid
formul
oral
deliveri
therapeut
bioavail
oral
administr
surviv
drastic
acid
enzymat
condit
stomach
therefor
aim
test
stabil
sirna
nanocomplex
sgf
prepar
accord
us
pharmacopeia
without
pepsin
interestingli
found
nanocomplex
retain
rnai
activ
even
subject
drastic
condit
min
fig
nanocomplex
stabl
sgf
without
pepsin
h
howev
presenc
pepsin
rnai
effect
decreas
time
depend
manner
supplementari
fig
indic
protect
sirna
acid
condit
prolong
period
time
howev
formul
approach
might
need
enhanc
pepsinresist
confirm
integr
nanocomplex
incub
sgf
via
nta
particl
size
analysi
fig
show
dissoci
remain
intact
condit
particl
size
increas
slightli
might
also
contribut
modest
decreas
activ
onbas
therapeut
repres
direct
way
translat
genom
data
therapeut
target
specif
dna
rna
sequenc
howev
bulki
hydrophil
natur
on
hinder
access
intracellular
target
across
plasma
membran
reason
mani
deliveri
technolog
develop
carri
on
across
cellular
membran
barrier
much
research
focu
specif
toward
develop
sirna
deliveri
vector
favor
pharmacodynam
profil
sirna
on
due
catalyt
natur
gene
silenc
effect
cation
lipid
formul
extens
util
sirna
vehicl
wide
use
transfect
reagent
invitro
eg
howev
limit
number
success
use
invivo
due
poor
colloid
stabil
toxicolog
concern
new
gener
lipidbas
sirna
vector
like
snalp
lipidoid
probabl
overcom
limit
howev
complex
multicompon
natur
system
could
limit
wide
use
altern
complexform
cpp
repres
singlestep
system
effici
deliveri
sirna
previous
shown
chemic
modifi
cpp
effici
deliv
sirna
invitro
sever
hardtotransfect
celllin
differ
organ
follow
system
deliveri
mice
without
associ
toxic
belong
pepfect
chemicallymodifi
cpp
famili
develop
lab
base
peptid
ad
chemic
modif
enhanc
complex
format
stabil
uptak
endosom
releas
case
ntermin
stearyl
contain
sever
ornithin
residu
stearyl
cpp
enhanc
complex
format
capac
cpp
nucleic
acid
enhanc
endosom
escap
hand
ornithin
nonstandard
amino
acid
would
render
peptid
resist
serum
proteas
prove
effici
deliveri
singlestrand
on
splice
correct
solut
solid
formul
studi
want
test
activ
deliv
sirna
whether
solid
formul
approach
would
also
success
applic
type
on
well
furthermor
want
extend
process
pharmaceut
develop
c
b
fig
induc
knockdown
endogen
gene
uniqu
kinet
profil
doserespons
curv
downregul
nanocomplex
cell
serumcontain
medium
solid
line
serumfre
medium
dot
line
concentr
mrna
deplet
ec
nm
nm
serum
serumfre
condit
respect
b
comparison
effici
one
select
dose
nm
sirna
transfect
lf
nake
sirna
without
transfect
reagent
control
sirna
unrel
sequenc
concentr
transfect
also
includ
c
kinet
downregul
use
nm
dose
sirna
transfect
serumcontain
serumfre
condit
lf
c
repres
kinet
h
show
timecours
studi
monitor
day
signific
differ
detect
mrna
remain
h
use
serum
free
lf
pb
h
pb
signific
differ
seen
well
treatment
serum
lf
h
pb
fig
nanocomplex
formul
solid
form
use
solid
dispers
techniqu
mannitol
solut
prepar
final
concentr
mgml
mq
water
nanocomplex
prepar
final
volum
mix
mannitol
solut
final
concentr
mannitol
reaction
mixtur
final
volum
mixtur
mixtur
dri
speedvac
h
temperatur
rang
transfect
dri
powder
reconstitut
mq
water
ad
well
hek
luciferasest
cell
treat
reconstitut
nanocomplex
serum
contain
serumfre
medium
cell
lyse
triton
luciferas
activ
measur
rnai
assay
result
present
percent
luciferas
express
rel
untreat
cell
control
nanocomplex
test
stabil
simul
gastric
condit
model
oral
administr
initi
test
abil
mediat
rnai
respons
report
celllin
luciferaseexpress
cell
use
interestingli
nanocomplex
mediat
effici
rnai
knockdown
luciferas
express
dosedepend
manner
differ
mr
downregul
luciferas
express
obtain
best
mr
fig
knockdown
achiev
rel
low
dose
sirna
effect
maintain
presenc
serum
next
use
nanocomplex
downregul
endogen
mrna
quantifi
respons
use
q
rtpcr
nanocomplex
demonstr
low
ec
serum
serumfre
media
knockdown
first
h
significantli
surpass
lf
rnaimax
fig
surprisingli
rnai
effect
maintain
day
confirm
sustain
activ
nanocomplex
endogen
gene
knockdown
also
demonstr
jurkat
suspens
celllin
known
hardtotransfect
supplementari
fig
proven
effici
differ
celllin
presenc
absenc
serum
want
test
activ
stabil
nanocomplex
formul
solid
form
sever
pharmaceut
benefit
solid
pharmaceut
form
wide
use
drug
formul
due
patient
conveni
high
stabil
profil
usual
use
oral
respiratori
administr
tablet
capsul
powder
inhal
furthermor
use
powder
inject
enhanc
stabil
intraven
formul
facilit
transport
storag
activ
stabl
solid
formul
sirna
could
add
new
opportun
applic
rnai
technolog
would
proofofconcept
deliveri
technolog
transform
sirna
power
laboratori
tool
viabl
drug
product
util
solid
formul
sirna
variou
pathogen
target
design
util
via
oral
pulmonari
pathway
exampl
sirna
hepat
c
viru
hcv
hypercholesterolemia
irrit
bowel
diseas
util
via
oral
rout
sirna
cystic
fibrosi
influenza
sever
acut
respiratori
syndrom
sar
infect
util
via
pulmonari
rout
appli
technolog
use
formul
singlestrand
on
solid
dispers
techniqu
base
mix
nanocomplex
solut
solubl
excipi
solid
dispers
dri
solvent
water
case
way
nanocomplex
uniformli
distribut
solid
matrix
evapor
water
dri
mixtur
vacuum
centrifug
util
speedvac
although
procedur
fairli
harsh
due
rel
high
temperatur
pressur
nanocomplex
subject
much
cheaper
scaleup
formul
mass
produc
compar
lyophil
techniqu
differ
excipi
test
data
shown
mannitol
concentr
fig
form
definit
nanocomplex
sirna
stabl
upon
dri
resuspens
nanocomplex
freshli
prepar
solid
formul
studi
use
nanoparticl
track
analysi
nta
system
freshli
prepar
nanocomplex
measur
water
b
freshli
prepar
nanocomplex
measur
fb
c
solid
formul
measur
water
solid
formul
measur
fb
graph
middl
panel
show
size
distribut
particl
particl
size
plot
xaxi
particl
concentr
plot
yaxi
graph
rightmost
panel
plot
size
vs
intens
vs
concentr
leftmost
panel
show
correspond
nta
video
frame
middl
panel
sampl
b
yellow
curv
repres
size
distribut
measur
vehicl
alon
fb
diamet
half
popul
lie
diamet
popul
lie
activ
mediat
rnai
effect
significantli
differ
freshlyprepar
nanocomplex
fig
result
agre
earlier
data
nanocomplex
singlestrand
on
confirm
inde
form
stabl
nanocomplex
withstand
formul
condit
better
visual
nanocomplex
studi
physicochem
properti
formul
ran
nta
measur
possess
better
resolut
convent
dl
techniqu
fig
mean
particl
size
significantli
differ
freshli
prepar
formul
solid
dispers
either
water
serumcontain
medium
fig
demonstr
nanocomplex
remain
intact
differ
media
withstand
dri
dispers
condit
howev
surfac
charg
zeta
potenti
depend
dispers
medium
dispers
water
nanocomplex
solid
formul
posit
charg
upon
dispers
biorelev
medium
without
serum
nanocomplex
becam
neg
charg
recent
shown
similar
behavior
nanocomplex
singlestrand
on
nanocomplex
takenup
cell
via
class
scaveng
receptor
net
neg
charg
nanocomplex
impli
recruit
pathway
final
want
test
stabil
nanocomplex
sgf
suitabl
oral
administr
interestingli
nanocomplex
maintain
rnai
respons
incub
sgf
min
even
presenc
pepsin
fig
acid
resist
maintain
period
h
howev
pepsin
decreas
activ
longer
period
incub
supplementari
fig
remark
demonstr
nanocomplex
protect
sirna
form
acid
condit
although
natur
phosphodiest
rna
without
chemic
modif
conclus
found
use
effici
deliveri
vector
sirna
variou
celllin
furthermor
nanocomplex
formul
solid
dosag
form
stabl
simul
gastric
condit
result
open
door
test
oral
cppbase
sirna
therapeut
anim
model
toward
develop
conveni
onbas
drug
product
new
class
therapeut
solid
formul
stabl
simul
gastric
acid
condit
solid
formul
prepar
use
nm
sirna
solid
dispers
method
appli
use
mannitol
concentr
freshli
prepar
nanocomplex
solid
formul
incub
sgf
without
pepsin
water
min
addit
cell
incub
hek
luciferas
stabl
cell
treat
nanocomplex
h
serumfre
medium
follow
addit
serum
final
concentr
incub
addit
h
cell
lyse
triton
luciferas
activ
measur
rnai
assay
result
present
percent
luciferas
express
rel
control
well
sgf
ad
b
solid
formul
reconstitut
water
incub
min
sgf
without
pepsin
mean
size
particl
nm
case
sgf
nm
sgf
pepsin
